Sign Up to like & get
recommendations!
1
Published in 2017 at "Prescriber"
DOI: 10.1002/psb.1543
Abstract: Opicapone (Ongentys) is a new once‐daily catechol‐O‐methyl transferase (COMT) inhibitor with a long duration of action allowing once‐daily dosing, licensed for adjunctive therapy in adults with Parkinson's disease and end‐of‐dose motor fluctuations. This article discusses…
read more here.
Keywords:
adjunctive therapy;
opicapone daily;
parkinson disease;
therapy parkinson ... See more keywords